These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35836330)

  • 1. Pharmacokinetics of intermittent dosed intravenous vancomycin in adult persons with cystic fibrosis.
    Lindley B; Bhakta Z; Gray K; Watanabe A; Leclair L; Young DC
    Pediatr Pulmonol; 2022 Nov; 57(11):2646-2651. PubMed ID: 35836330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics and pharmacodynamics of continuous infusion vancomycin in adult people with cystic fibrosis.
    Lindley B; Bhakta Z; Leclair L; Young DC
    Pediatr Pulmonol; 2024 Jan; 59(1):89-94. PubMed ID: 37792309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.
    Stockmann C; Sherwin CM; Zobell JT; Lubsch L; Young DC; Olson J; Noyes BE; Ampofo K; Spigarelli MG
    Pharmacotherapy; 2013 Dec; 33(12):1288-96. PubMed ID: 23824677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and target attainment analysis of vancomycin after intermittent dosing in adults with cystic fibrosis.
    Yellepeddi VK; Lindley B; Radetich E; Kumar S; Bhakta Z; Leclair L; Parrot M; Young DC
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0099223. PubMed ID: 38059634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftaroline vs vancomycin for the treatment of acute pulmonary exacerbations in pediatric patients with cystic fibrosis.
    Branstetter J; Searcy H; Benner K; Yarbrough A; Crowder C; Troxler B
    Pediatr Pulmonol; 2020 Dec; 55(12):3337-3342. PubMed ID: 32803907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.
    Fusco NM; Toussaint KA; Prescott WA
    Ann Pharmacother; 2015 Apr; 49(4):458-68. PubMed ID: 25583881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Vancomycin Trough Concentration With Response to Treatment for Acute Pulmonary Exacerbation of Cystic Fibrosis.
    Fusco NM; Francisconi R; Meaney CJ; Duman D; Frederick CA; Prescott WA
    J Pediatric Infect Dis Soc; 2017 Sep; 6(3):e103-e108. PubMed ID: 28903517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftaroline versus vancomycin for treatment of acute pulmonary exacerbations of cystic fibrosis in adults.
    Esquivel MD; Monogue ML; Smith GS; Finklea JD; Sanders JM
    J Glob Antimicrob Resist; 2022 Mar; 28():67-70. PubMed ID: 34936925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of antibiotics for methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.
    Zobell JT; Epps KL; Young DC; Montague M; Olson J; Ampofo K; Chin MJ; Marshall BC; Dasenbrook E
    Pediatr Pulmonol; 2015 Jun; 50(6):552-9. PubMed ID: 25559432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous infusion vancomycin for treatment of methicillin-resistant Staphylococcus aureus in cystic fibrosis patients.
    Fung L
    Ann Pharmacother; 2012 Oct; 46(10):e26. PubMed ID: 23032658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I, Dose-Escalating Study of the Safety and Pharmacokinetics of Inhaled Dry-Powder Vancomycin (AeroVanc) in Volunteers and Patients with Cystic Fibrosis: a New Approach to Therapy for Methicillin-Resistant Staphylococcus aureus.
    Waterer G; Lord J; Hofmann T; Jouhikainen T
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31964790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous vancomycin in a pediatric cystic fibrosis patient.
    McKinzie CJ; Esther CR; Vece TJ
    Pediatr Pulmonol; 2018 Jan; 53(1):E4-E5. PubMed ID: 29193836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics.
    Epps QJ; Epps KL; Young DC; Zobell JT
    Pediatr Pulmonol; 2020 Jan; 55(1):33-57. PubMed ID: 31609097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Evaluation of Vancomycin Area Under the Curve Estimation Methods for Children Treated for Acute Pulmonary Exacerbations of Cystic Fibrosis Due to Methicillin-Resistant Staphylococcus aureus.
    Stockmann C; Olson J; Rashid J; Lubsch L; Young DC; Hersh AL; Frymoyer A; Ampofo K; Liu X; Wang Y; Sherwin CMT; Zobell JT
    J Clin Pharmacol; 2019 Feb; 59(2):198-205. PubMed ID: 30371946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness of Vancomycin Versus Linezolid for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis.
    Fusco NM; Meaney CJ; Frederick CA; Prescott WA
    Ann Pharmacother; 2020 Mar; 54(3):197-204. PubMed ID: 31658825
    [No Abstract]   [Full Text] [Related]  

  • 16. Eradication strategy for persistent methicillin-resistant Staphylococcus aureus infection in individuals with cystic fibrosis--the PMEP trial: study protocol for a randomized controlled trial.
    Jennings MT; Boyle MP; Weaver D; Callahan KA; Dasenbrook EC
    Trials; 2014 Jun; 15():223. PubMed ID: 24925006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous vs. intermittent vancomycin therapy for Gram-positive infections not caused by methicillin-resistant Staphylococcus aureus.
    Duszynska W; Taccone FS; Hurkacz M; Wiela-Hojenska A; Kübler A
    Minerva Anestesiol; 2016 Mar; 82(3):284-93. PubMed ID: 26184702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.
    Dezube R; Jennings MT; Rykiel M; Diener-West M; Boyle MP; Chmiel JF; Dasenbrook EC
    J Cyst Fibros; 2019 May; 18(3):357-363. PubMed ID: 30131297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of model-informed precision dosing on achievement of vancomycin exposure targets in pediatric patients with cystic fibrosis.
    Frymoyer A; Schwenk HT; Brockmeyer JM; Bio L
    Pharmacotherapy; 2023 Oct; 43(10):1007-1014. PubMed ID: 37401162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.
    Kidd JM; Sakon CM; Oleksiuk LM; Cies JJ; Pettit RS; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.